ClinicalTrials.gg
RecruitingNCT04730700MEEUpdated Oct 6, 2026

Evaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management.

An interventional study of Radiofrequency Ablation with MEE and Conventional Medical Management in Chronic Low-back Pain, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Kansas Medical Center · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2020; still recruiting 5 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Planned enrollment
390th of 623
50 · median 79
Started
2020
with 31 others
No phase
408 of 712
62 open now
Primary completion
2026-11
later than 34 of 125 live
Registered
517th of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is the 390th largest by planned enrollment of the 623 interventional ones that give a count, is one of 32 that started in 2020, is one of 408 with no phase, reaches primary completion later than 34 of the 125 other live ones, and was the 517th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to better understand how people feel after a radiofrequency ablation standard of care surgery using a different type of needle (multi-tined expandable electrode/MEE) in comparison to receiving conventional medical management (CMM) techniques.

03

Conditions studied

  • Chronic Low-back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years old.
  • Patients with pain lasting at least 6 months.
  • Patients with history of non-radiating low back pain.
  • Patient who had two diagnostic medial branch blocks (MBB) with significant (>50%) improvement on both injections.
  • Patient has signed study-specific .
  • Patient has the necessary mental capacity to participate and is physically able to comply with study protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Patient with low back pain with radiation or involvement of pain going into their legs below their knees.
  • Patient did not receive satisfactory relief from diagnostic MBB (\<50% relief).
  • Patient is unable to receive radiation exposure.
  • Patient is currently pregnant.
  • Patient has a current local overlying low back or systemic infection.
  • Patient currently receiving or seeking workers compensation, disability remuneration, and/or involved in injury litigation.
  • Known or suspected drug or alcohol abuse.
  • Diagnosed psychiatric disease (e.g., schizophrenia, major depression, personality disorders) that could interfere with study participation.
  • Patient is participating in an study or has been involved in an investigational study within 3 months prior to evaluation for participation.
  • Patient has an implanted intrathecal pump or spinal neuromodulation device.
  • Patient currently on daily oral morphine equivalent (OME) of 50.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Radiofrequency ablation (RFA) with MEE

    Radiofrequency ablation involves a minimally invasive procedural technique. It uses radiofrequency waves to burn the nerve causing pain. This nerve will no longer be able to send pain signals to your brain. For this study, the multi-tined expandable electrode needle will be used. This needle will result in a larger treatment area. This may result in better pain relief and longer lasting pain relief. If you undergo the radiofrequency ablation procedure you will have pain medication injected where the ablation will be done. The procedure will take about 20 mins to complete. You will be allowed to go home afterward.

    Procedure: Radiofrequency Ablation with MEE

  • Active comparator
    Conventional Medical Management (CMM) Treatment Only

    Your current standard of care treatment may already consist of some CMM therapies. Standard of care includes a variety of intervention types such as medication, physical therapy, home exercise programs, back brace, walking aid, and chiropractic care.

    Behavioral: Conventional Medical Management

Interventions

  • ProcedureRadiofrequency Ablation with MEE

    RFA will be performed in the usual fashion utilizing the MEE instead of the RFA needles routinely used at each institution.

  • BehavioralConventional Medical Management

    Conventional medical management (CMM), which may include physical therapy, home exercise programs, pain medication, and other conservative therapies such as back brace, walking aid, and chiropractic care.

06

What researchers measure

Primary outcomes

  1. The mean visual analog scale (VAS) between the two group

    will be compared using an independent samples t-test

    Time frame: 12 months

Secondary outcomes

  1. Observe the incidence of complications associated with MEE while utilizing this device

    Number of complications will be analyzed using Independent samples T-Test if there is a normal distribution of complications. In the event of a binary outcome for complications, Chi-square Test will be used.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2020 (actual). Primary completion is estimated for Nov 2026, 71 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 71 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2020
First posted
Jan 29, 2021
StartActual
Dec 17, 2020
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04730700
Responsible party
Dawood Sayed, MD (Study Principal Investigator, University of Kansas Medical Center) — Principal investigator
First posted
Jan 29, 2021
Start date
Dec 17, 2020
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Angie Ballew, DC, MS
Contact
aballew@kumc.edu
(913) 945-7420
Dawood Sayed, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion